These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32553868)

  • 1. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
    Ricci F; Murgia X; Razzetti R; Pelizzi N; Salomone F
    Pediatr Res; 2017 Feb; 81(2):369-375. PubMed ID: 27973472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.
    Sweet DG; Turner MA; Straňák Z; Plavka R; Clarke P; Stenson BJ; Singer D; Goelz R; Fabbri L; Varoli G; Piccinno A; Santoro D; Speer CP
    Arch Dis Child Fetal Neonatal Ed; 2017 Nov; 102(6):F497-F503. PubMed ID: 28465315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral and lung effects of a new generation synthetic surfactant with SP-B and SP-C analogs in preterm lambs.
    Rey-Santano C; Mielgo VE; Murgia X; Gomez-Solaetxe MA; Salomone F; Bianco F; Pelizzi N; Loureiro B; López de Heredia Y Goya J
    Pediatr Pulmonol; 2017 Jul; 52(7):929-938. PubMed ID: 28221717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW; Oh M; Sin JB
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Natural versus Synthetic Surfactant with SP-B and SP-C Analogs in a Porcine Model of Meconium Aspiration Syndrome.
    Salvesen B; Curstedt T; Mollnes TE; Saugstad OD
    Neonatology; 2014; 105(2):128-35. PubMed ID: 24356240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation.
    Dargaville PA; Kamlin CO; De Paoli AG; Carlin JB; Orsini F; Soll RF; Davis PG
    BMC Pediatr; 2014 Aug; 14():213. PubMed ID: 25164872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome.
    Mikolka P; Curstedt T; Feinstein R; Larsson A; Grendar M; Rising A; Johansson J
    Physiol Rep; 2021 Jan; 9(1):e14700. PubMed ID: 33403805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
    Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
    JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
    Sato A; Ikegami M
    PLoS One; 2012; 7(7):e39392. PubMed ID: 22808033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
    Malloy CA; Nicoski P; Muraskas JK
    Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic surfactant CHF5633 vs poractant alfa.
    Razak A; Suresh Gautham K
    J Pediatr; 2020 Dec; 227():325-326. PubMed ID: 32798565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.